Literature DB >> 20567123

[A case of primary gastric choriocarcinoma treated by curative operation after neoadjuvant chemotherapy with S-1/CDDP].

Yoshinori Shimizu1, Mitsuo Kusano, Akira Fujimori, Tomokazu Kusano, Junichi Taka, Takeshi Aoki, Masahiko Murakami.   

Abstract

We experienced a case of primary gastric choriocarcinoma(PGC)treated by curative operation after neoadjuvant chemotherapy with S-1/CDDP. Gastric endoscopy was carried out on this 43-year-old woman with epigastric discomfort and revealed an ulcerative lesion in her stomach. Choriocarcinoma in the gastric lesion was pathologically shown by endoscopic biopsy, so we diagnosed the patient without another primary lesion as PGC. The patient was initially treated by five courses of neoadjuvant chemotherapy with S-1/CDDP due to the metastases of Virchow and intraabdominal lymph nodes, and then a curative operation could be performed because of disappearance of the lymph node metastases by neoadjuvant chemotherapy. The patient was continuously treated by S-1 after gastrectomy but was dead due to the multiple metastases of the liver and adrenals, and the multiple recurrences of lymph nodes four months after the surgery. Further therapeutic strategy by chemotherapies against PGC is needed to ameliorate the prognosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20567123

Source DB:  PubMed          Journal:  Gan To Kagaku Ryoho        ISSN: 0385-0684


  2 in total

Review 1.  Complete response to multidisciplinary therapy in a patient with primary gastric choriocarcinoma.

Authors:  Kazuhiro Takahashi; Shigeki Tsukamoto; Ken Saito; Nobuhiro Ohkohchi; Katsu Hirayama
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

2.  Treatment of stage IV gastric cancer with induction chemotherapy using S-1 and cisplatin followed by curative resection in selected patients.

Authors:  Masaaki Saito; Hirokazu Kiyozaki; Osamu Takata; Koichi Suzuki; Toshiki Rikiyama
Journal:  World J Surg Oncol       Date:  2014-12-30       Impact factor: 2.754

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.